Q-omics provides the consensus-scored PGM5P4 profile across patient tissues and cancer cell-line models. PGM5P4 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, PGM5P4 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, PGM5P4 RNA expression shows 16,694 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BRCA, BLCA, and LSCC as cancer lineages where PGM5P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PGM5P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PGM5P4 survival associations across molecular data types. PGM5P4 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PGM5P4 RNA expression–survival associations across cancer types. High PGM5P4 expression shows unfavorable associations in ACC and COAD, but favorable associations in BRCA, MESO, UCS and LUAD. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for PGM5P4 RNA expression.
This table summarizes PGM5P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for PGM5P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PGM5P4 shows lower tumor expression in BLCA, KICH, COAD, THCA, LUSC and KIRP. The BLCA box plot shows higher PGM5P4 RNA expression in normal versus tumor tissue (log2 FC = −4.730, t-test p < 0.001).
This table shows molecular features associated with PGM5P4 in patient tissues and cancer cell lines. In patient samples, PGM5P4 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PGM5P4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC.
